RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
👇👇👇
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @notthefirstpete: More good vaccine news 👏👏👏 Go, @SaulFaust @unisouthampton @RDsouthampton @OxfordMedSci https://t.co/gCbmwE…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @rasmus_kleis: So far, I think reporting on #covid19 vaccines have had to rely on- Pfizer-BioNTech press release Sputnik press release…
RT @rasmus_kleis: So far, I think reporting on #covid19 vaccines have had to rely on- Pfizer-BioNTech press release Sputnik press release…
@hildabast Hi Hilda, do you mean this file? https://t.co/Ho0w7HSeKh
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Oxford vaccine phase II trial results. 👍🏻 “vaccine was safe and well tolerated... Antibody responses against SARS-CoV-2 spike protein were induced in all age groups and were boosted and maintained at 28 days after booster vaccination, including in the 70
RT @angel_h_merino: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @trishgreenhalgh: Oxford vaccine is safe and generates a good immune response in almost everyone who receives it.
So far, I think reporting on #covid19 vaccines have had to rely on- Pfizer-BioNTech press release Sputnik press release Moderna press release And peer-reviewed article from Oxford/AstraZeneca effort. Glad the BBC notes difference https://t.co/OPQ6oe0sNm
RT @JPHorwood: Good news! Oxford vaccine is safe, with data showing it triggers a strong immune response and good tolerance in older adults
Vacuna #COVID19 de @UniofOxford @AstraZeneca ➡️ similares resultados de seguridad e inmunogenicidad en los adultos sanos de más edad que en aquellos de entre 18 y 55 años Es un EECC fase 2 y por tanto, no evalúa eficacia. El ensayo fase 3 ya está en march
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial - The Lancet https://t.co/rUU7QnHwKW
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
This is want I wanted to see to start believing- a scientific paper published. Thank you
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @MaxCRoser: New results from the Oxford vaccine trial just got published in The Lancet. It studied whether the immune response provoked…
RT @trishgreenhalgh: Oxford vaccine is safe and generates a good immune response in almost everyone who receives it.
RT @mariaramirezNY: Los resultados de la fase 2 del ensayo de la vacuna de Oxford explicados (ya está en la fase 3, que es la final y sobre…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Es confirmen els resultats “encoratjadors” de la fase II de les proves de la vacuna d’Oxford. Mostren que genera una forta resposta immunològica en la gent gran, que la tolera millor que els més joves. Cal veure si amb això n’hi ha prou per aturar la Covid
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
*I know nothing about this topic, but it does seem very British that the Americans have cracked into it and are shoving it in the world’s faces, whilst we’re penning academic articles in print about progress a few months ago. I’d expect a root and branch p
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @PabloFuente: #COVID19 Los datos, que se conocieron en parte el mes pasado, y que ahora son ahora publicados en su totalidad en The Lanc…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
#COVID19 Los datos, que se conocieron en parte el mes pasado, y que ahora son ahora publicados en su totalidad en The Lancet. https://t.co/y2CHkuhpT2
RT @graham74GC: Great to see some published #COVID19 vaccine data from the Oxford vaccine. Similar antibody and T-cell responses seen acros…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
A Ciência faz-se assim. https://t.co/kWiTnp7s5E
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine in a prime-boost regimen in young and old adults. "Here we found similar safety and immunogenicity of ChAdOx1 nCoV-19 in older adults compared with younger adults" https://t.co/0BIY62hz7w
RT @TheLancet: Authors note that their new findings could be encouraging if the immune responses found in their study are associated with p…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
That's what we all want. Yesterday, Oxford published their preliminary findings in @TheLancet for the COVID-19 vaccine (it's an adenovirus-vectored vaccine). The trial is yet to be complete, and what the investigators present here is not 'efficacy'. http
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
More good news on the vaccine front The ChAdOx1 vaccine (astrazeneca, COVIDSHIELD in India) produced a strong immune response in the highest-risk group of older adults (60-70 year olds) in phase-2 trials. https://t.co/wVCtzqJtAB
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @pav_akhtar: The Oxford-AstraZeneca #COVID19 #vaccine is showing level safety and immunogenicity across age groups. Such promising news!
Good news! Oxford vaccine is safe, with data showing it triggers a strong immune response and good tolerance in older adults
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
Great to see some published #COVID19 vaccine data from the Oxford vaccine. Similar antibody and T-cell responses seen across age groups (18-55; 56-69; 70+). Slightly better tolerated in older age (no drug rel SAEs in all). Eagerly awaiting efficacy data.
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
I would wait for this vaccine, seems less complicated than others, closer 2 home, but am worried about choice? if vaccination is started with other suppliers.
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @CT_Bergstrom: Phase 2 results from Astrazeneca: encouraging if somewhat overshadowed by Pfizer and Moderna https://t.co/eK9mYa3aRJ
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @fisicoperaria: Ah ma quindi si possono pubblicare i dati di efficacia di un vaccino su una rivista scientifica in peer review? Perché s…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @MaxCRoser: New results from the Oxford vaccine trial just got published in The Lancet. It studied whether the immune response provoked…
RT @CT_Bergstrom: Phase 2 results from Astrazeneca: encouraging if somewhat overshadowed by Pfizer and Moderna
🍾🍾
Ah ma quindi si possono pubblicare i dati di efficacia di un vaccino su una rivista scientifica in peer review? Perché sembrava che si potessero fare a riguardo solo comunicati stampa. #COVID19 https://t.co/vKQ3i20Row
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Great news👏👏👏👏💙
La vacuna de Moderna y de Pfizer se la pondría un inversor en bolsa, la de la Universidad de Oxford me la pondría yo. https://t.co/HeMsqkclGz
RT @JennerInstitute: The Oxford-AstraZeneca #COVID19 #vaccine is safe and immunogenic across age groups https://t.co/0sf2GSdHTC
@LFVCL @SethMacFarlane More science: Lancet article https://t.co/h0T0LACa6T
RT @teozka: Resultados de fase 2 de vacuna Oxford/AstraZeneca publicados hoy en Lancet. Al ser fase 2 el estudio de enfoca en inmunogenicid…